Lilly to file for next-gen obesity drug approval in early 2027
Eli Lilly has officially adjusted its timeline for the next-generation obesity drug, retatrutide. The pharmaceutical firm announced that it will file for regulatory approval in the first quarter of 2027. This update shifts the schedule from initial internal targets to ensure all manufacturing and quality-control data meet strict standards.
Retatrutide has performed well in recent Phase 3 clinical trials. In a study focused on adults with obesity and Type 2 diabetes, participants experienced weight loss of up to 20.8 percent over 80 weeks. A separate trial involving patients with severe obesity and cardiovascular issues showed weight reductions of up to 22.6 percent during the same timeframe. These results point to potential uses for the drug beyond weight loss, including treatment for obstructive sleep apnea and knee osteoarthritis pain.
The medication functions by targeting three specific hormones: GLP-1, GIP, and glucagon. This triple-action approach distinguishes it from other weight-loss products currently available, which typically focus on one or two of these hormones. Analysts from TD Cowen noted that the drug could reach 3.8 billion dollars in sales by 2030, marking it as a primary pillar for the company alongside existing offerings like Zepbound and the oral medication Foundayo.
While the company prepares for its 2027 filing, the competitive landscape remains active. Novo Nordisk recently filed a lawsuit in New Jersey against Eli Lilly, claiming the company engaged in false advertising regarding the performance of its weight-loss products. Despite legal challenges and the adjusted filing timeline, internal projections remain focused on the clinical benefits observed in recent trials. Patients may experience standard side effects such as nausea, diarrhea, and constipation, which align with the current profile of the GLP-1 class of drugs.